TGF-beta IL-6 axis mediates selective and adaptive mechanisms of resistance to molecular targeted therapy in lung cancer - Wikidata - awgldk - TriplyDB

TGF-beta IL-6 axis mediates selective and adaptive mechanisms of resistance to molecular targeted therapy in lung cancer

TGF-beta IL-6 axis mediates selective and adaptive mechanisms of resistance to molecular targeted therapy in lung cancer

http://www.wikidata.org/entity/Q34100276

about

MED12 controls the response to multiple cancer drugs through regulation of TGF-β receptor signaling Predictive factors of activity of anti-programmed death-1/programmed death ligand-1 drugs: immunohistochemistry analysis Pushing tumor cells towards a malignant phenotype: stimuli from the microenvironment, intercellular communications and alternative roads Signaling cross-talk in the resistance to HER family receptor targeted therapy Involvement of inflammation and its related microRNAs in hepatocellular carcinoma Epithelial-to-mesenchymal transition is not required for lung metastasis but contributes to chemoresistance Loss of p53 attenuates the contribution of IL-6 deletion on suppressed tumor progression and extended survival in Kras-driven murine lung cancer Distinct clinical outcomes of non-small cell lung cancer patients with epidermal growth factor receptor (EGFR) mutations treated with EGFR tyrosine kinase inhibitors: non-responders versus responders MicroRNA-147 induces a mesenchymal-to-epithelial transition (MET) and reverses EGFR inhibitor resistance The quest to overcome resistance to EGFR-targeted therapies in cancer.Antitumor efficacy of the anti-interleukin-6 (IL-6) antibody siltuximab in mouse xenograft models of lung cancer.JAK1 activates STAT3 activity in non-small-cell lung cancer cells and IL-6 neutralizing antibodies can suppress JAK1-STAT3 signaling A high-affinity protein binder that blocks the IL-6/STAT3 signaling pathway effectively suppresses non-small cell lung cancer.Glucose metabolism-targeted therapy and withaferin A are effective for epidermal growth factor receptor tyrosine kinase inhibitor-induced drug-tolerant persisters.High throughput determination of TGFβ1/SMAD3 targets in A549 lung epithelial cells STAT3 is activated by JAK2 independent of key oncogenic driver mutations in non-small cell lung carcinoma.Properties of resistant cells generated from lung cancer cell lines treated with EGFR inhibitors.Image-guided thermal ablation of tumors increases the plasma level of interleukin-6 and interleukin-10.Profiling human protein degradome delineates cellular responses to proteasomal inhibition and reveals a feedback mechanism in regulating proteasome homeostasis.EGFR-mutated lung cancer: a paradigm of molecular oncology.Regulation of epidermal growth factor receptor signaling and erlotinib sensitivity in head and neck cancer cells by miR-7 The role of epithelial plasticity in prostate cancer dissemination and treatment resistance A systems view of epithelial-mesenchymal transition signaling states.Mesenchymal phenotype predisposes lung cancer cells to impaired proliferation and redox stress in response to glutaminase inhibition Redundant kinase activation and resistance of EGFR-tyrosine kinase inhibitors.SOCS3-mediated regulation of inflammatory cytokines in PTEN and p53 inactivated triple negative breast cancer model Heterogeneity maintenance in glioblastoma: a social network From the bench to bedside: biological and methodology considerations for the future of companion diagnostics in nonsmall cell lung cancer.Targeting ErbB3-mediated stromal-epithelial interactions in pancreatic ductal adenocarcinoma.MyD88-Dependent Signaling Decreases the Antitumor Efficacy of Epidermal Growth Factor Receptor Inhibition in Head and Neck Cancer Cells.Protein kinase Cα mediates erlotinib resistance in lung cancer cells.A microRNA gene expression signature predicts response to erlotinib in epithelial cancer cell lines and targets EMT.Expression of the IGF axis is decreased in local prostate cancer but enhanced after benign prostate epithelial differentiation and TGF-β treatment.Interleukin 6 augments lung cancer chemotherapeutic resistance via ataxia-telangiectasia mutated/NF-kappaB pathway activation Xilonix, a novel true human antibody targeting the inflammatory cytokine interleukin-1 alpha, in non-small cell lung cancer Homoharringtonine induces apoptosis and inhibits STAT3 via IL-6/JAK1/STAT3 signal pathway in Gefitinib-resistant lung cancer cells.Complexity in the signaling network: insights from the use of targeted inhibitors in cancer therapy.Low Prognostic Nutritional Index Correlates with Worse Survival in Patients with Advanced NSCLC following EGFR-TKIs ZEB1 Mediates Acquired Resistance to the Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer.Upregulated interleukin-6 expression contributes to erlotinib resistance in head and neck squamous cell carcinoma.

P2860

Q24304423-BDAB4A3B-76A6-496A-90D0-611692C457EB Q26769728-2291ED9F-DA4A-4B78-ACF1-E5351ABDEA99 Q26830075-6C9E4918-9169-47FC-B8C3-B7467C32A111 Q27027778-CB3616C8-CD4D-4847-A585-FD693824D013 Q28079138-F3B6555E-2779-4A29-B748-38F1E2BBD2EE Q28269714-0D177F24-6F30-44DA-BB82-341C61D3B8AA Q28535183-ED14FFA1-DCB7-40B4-9CEE-0E8F633E868E Q28537922-ED4A27A8-35CC-47C4-B00A-51DF75F0A35B Q28538690-2A5C03D9-290E-4098-9CD5-58B1C8C3AA62 Q33725976-09D5BC3F-7620-4CE7-8324-87BD12DD3F08 Q33756818-74FFB8BC-EC64-4AEF-BF5A-B5E9ED2E8B69 Q33854898-3ECD3F1D-36DE-43B3-AF0B-360A1847D168 Q33870701-2092F3B1-466D-4C3D-9BB1-D83C444CDD68 Q33873274-861F0470-1B2C-460C-AC2F-FF70070F5E59 Q33916249-F4EE8943-136C-4743-AF01-96D416214ED9 Q34154674-07199C52-833D-4280-9BA6-66E5F4C15997 Q34203720-DB0C26B8-327E-41E2-852C-DCEC61B96BD2 Q34205626-CE238FF8-FE7F-44B3-AE7A-63F9A7F3E9F0 Q34289909-9E54CB47-B66E-4358-A6FA-C94074C56F94 Q34406334-C13C2D31-23E8-4279-ACE5-DD925A8413F6 Q34463471-37F12520-8951-468E-9A82-B2FF0C73E930 Q34505037-22C929C6-5834-415D-B889-4B0AF1BC18E7 Q34579646-FFF75EAF-AECC-4FF8-97DE-5188BE0A1A92 Q34691457-B6B14B30-05F0-4C75-92C4-3FCF9A918D1B Q34704781-0410D6FE-7BF2-4E9D-BDC9-60A617CB6983 Q34850997-7BDE46BF-BDB4-4D8A-A5AC-33B063050F83 Q35050894-8C405EF4-67BC-4095-AC8D-4A6FE8EAA7FF Q35117568-9A75BE3A-61A1-433B-8368-DAFB9CB69111 Q35208054-3018CA2A-59A5-43B5-8E06-66C8C8C94CA7 Q35463538-69330CAF-9F59-4BC6-837B-427A4B9420F4 Q35531840-1E80AA55-2774-4E3E-9C60-4EE98D577AFE Q35653719-77B0974F-8DDC-4F70-B2F2-54E786C4758A Q35679456-986ECF66-8326-468B-A193-DDCA8E316711 Q35713579-D4AA680E-D1BA-4A5F-A72B-AD61431B624C Q35786634-08A0B0B5-93B2-459A-8630-C6B348C384A6 Q35844693-8D03BFD7-C436-47C4-8948-76F4EC8759D2 Q35882137-6534F491-B7C1-445B-AF38-B1A338A06723 Q35897794-B597F455-368F-4471-BDC9-63F5732D5A37 Q35898981-226D197E-D5AB-4057-B96D-68A3066010DB Q35912079-73380949-B095-417C-9022-F5DD4ED0BFC6

P2860

TGF-beta IL-6 axis mediates selective and adaptive mechanisms of resistance to molecular targeted therapy in lung cancer

http://www.wikidata.org/entity/Q34100276

description

2010 nî lūn-bûn

@nan

2010 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

TGF-beta IL-6 axis mediates se ...... argeted therapy in lung cancer

@ast

TGF-beta IL-6 axis mediates se ...... argeted therapy in lung cancer

@en

TGF-beta IL-6 axis mediates se ...... argeted therapy in lung cancer

@nl

type

label

TGF-beta IL-6 axis mediates se ...... argeted therapy in lung cancer

@ast

TGF-beta IL-6 axis mediates se ...... argeted therapy in lung cancer

@en

TGF-beta IL-6 axis mediates se ...... argeted therapy in lung cancer

@nl

prefLabel

TGF-beta IL-6 axis mediates se ...... argeted therapy in lung cancer

@ast

TGF-beta IL-6 axis mediates se ...... argeted therapy in lung cancer

@en

TGF-beta IL-6 axis mediates se ...... argeted therapy in lung cancer

@nl

P1433

Q34100276-1F0AEB6F-C5EA-4A72-B74E-C7C55BAD9972

P1476

Q34100276-962B453F-B42A-4015-B71B-17C128C9E0E2

P2093

Q34100276-028D38FB-6769-4808-B71F-E4EEF57C7BDC

Q34100276-2A1EB129-5F98-4272-99F0-5C89A3A1DC75

Q34100276-469D42FA-B579-4B39-B894-29C74B369776

Q34100276-4EE8B748-6EE7-4689-8C4F-92348CDC081B

Q34100276-54FFC3B8-F956-4EE1-A6DD-F7807327B817

Q34100276-614213E7-5BA5-46E5-9C57-51EE065D52D6

Q34100276-7F625F9B-6FF2-4F53-8E13-45831BEABD2D

Q34100276-8CD1B0D9-8B1F-489F-AE5A-DDC415C7C73E

Q34100276-B7BC2C33-FBC9-4166-A854-7ADA37C5F424

Q34100276-BB090B16-4785-4F76-9AB0-8339E39FDF5B

P2860

Q34100276-15C72364-7554-4D4D-A23C-24B8D3B32E52

Q34100276-1A9C46DF-483D-4CA8-ACB2-0D3089B20EC0

Q34100276-2FC9465A-90E4-4817-8199-80B180555637

Q34100276-39902CB1-A66F-485E-9B2B-611AAD4456EE

Q34100276-3A461C0B-9C6E-4C21-A69F-771F7D96C55C

Q34100276-3FCAE4A1-5034-42D0-8E6A-C293BD28ACFC

Q34100276-76FA3C89-3ACB-4BD3-B0B2-20DA02EF3C53

Q34100276-824057BC-0AB4-49EB-AE2A-756EC27E00BD

Q34100276-83EFE8B3-F8C8-49A5-9B8A-DD4CDAA38370

Q34100276-9472A08C-9E1F-4C54-BAC7-0B0F31A92778

P304

Q34100276-10B75549-0073-4920-828D-DBD9F261F844

P31

Q34100276-230D5D42-7BDA-43BC-87BA-4259222D799A

P356

Q34100276-3269ADA6-7B4A-4643-96DC-0377906E64CD

P407

Q34100276-EB67CD12-07FA-4B2A-9742-2A9D9D677C05

P433

Q34100276-4FFA31E3-3839-454B-9506-A430DB414C6D

P478

Q34100276-64A063BD-EA91-41E8-B7DC-EDC994CA2D4B

P50

Q34100276-1D2954B1-F294-4B01-9A9D-6D0032166433

Q34100276-90B8CC42-243C-48CD-94D8-F19DC71CE9CF

P577

Q34100276-47306F20-845B-47C6-AE09-37F323256B58

P5875

Q34100276-277EE279-812F-423B-819D-CFDD592447C8

P698

Q34100276-D1C5FDD3-D6B5-4C12-8DC2-03A53E40BBB8

P932

Q34100276-809ED12E-B063-4B6E-970F-2C694649C643

P356

PNAS.1009472107

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

TGF-beta IL-6 axis mediates se ...... argeted therapy in lung cancer

@en

P2093

Brendon Stiles

http://www.w3.org/2001/XMLSchema#string

Chris Johns

http://www.w3.org/2001/XMLSchema#string

Ding Cheng Gao

http://www.w3.org/2001/XMLSchema#string

Matthew Camiolo

http://www.w3.org/2001/XMLSchema#string

Michaela Schlederer

http://www.w3.org/2001/XMLSchema#string

Nasser Altorki

http://www.w3.org/2001/XMLSchema#string

Raffaella Sordella

http://www.w3.org/2001/XMLSchema#string

Silvia Fenoglio

http://www.w3.org/2001/XMLSchema#string

Trine Lindsted

http://www.w3.org/2001/XMLSchema#string

Vivek Mittal

http://www.w3.org/2001/XMLSchema#string

P2860

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling.

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

Identification and expansion of the tumorigenic lung cancer stem cell population

Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR

Alterations in genes of the EGFR signaling pathway and their relationship to EGFR tyrosine kinase inhibitor sensitivity in lung cancer cell lines.

Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.

Stat3 protects against Fas-induced liver injury by redox-dependent and -independent mechanisms.

P304

15535-15540

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1073/PNAS.1009472107

http://www.w3.org/2001/XMLSchema#string

P407

P433

35

http://www.w3.org/2001/XMLSchema#string

P478

107

http://www.w3.org/2001/XMLSchema#string

P50

P577

2010-08-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

45660037

http://www.w3.org/2001/XMLSchema#string

P698

20713723

http://www.w3.org/2001/XMLSchema#string

P932

2932568

http://www.w3.org/2001/XMLSchema#string